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Esophageal carcinoma is the most rapidly increasing tumor in the United States and has a dismal 15% 5-year survival.
Immunotherapy has been proposed to improve patient outcomes; however, no immunocompetent esophageal carcinoma model
exists to date to test this approach. We developed two mouse models of esophageal cancer by inoculating immunocompetent mice
with syngeneic esophageal cell lines transformed by cyclin-D1 or mutant HRAS
G12V and loss of p53. Similar to humans, surgery and
adjuvant chemotherapy (cisplatin and 5-fluorouracil) demonstrated limited efficacy. Gene-mediated cyototoxic immunotherapy
(adenoviral vector carrying the herpes simplex virus thymidine kinase gene in combination with the prodrug ganciclovir; AdV-tk/
GCV) demonstrated high levels of in vitro transduction and efficacy. Using in vivo syngeneic esophageal carcinoma models,
combining surgery, chemotherapy and AdV-tk/GCV improved survival (P¼0.007) and decreased disease recurrence (Po0.001).
Mechanistic studies suggested that AdV-tk/GCV mediated a direct cytotoxic effect and an increased intra-tumoral trafficking of CD8
T cells (8.15% vs 14.89%, P¼0.02). These data provide the first preclinical evidence that augmenting standard of care with
immunotherapy may improve outcomes in the management of esophageal carcinoma.
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Introduction
Esophageal cancer is the seventh most common cause of
cancer death among men in the United States. At
diagnosis, approximately 50% of patients have advanced,
incurable disease, which is associated with a 5-year overall
survival of 6%.
1 Surgery offers the best opportunity for
long-term survival; however, only 25% of patients diag-
nosed qualify for surgical resection. Even with surgery,
the 5-year survival rate of this cohort is only 32%.
1 The
poor survival is due to the high postoperative recurrence
rate ranging from 60 to 80%. To address the issue of
recurrences, adjuvant chemotherapy and radiation have
been utilized.
2–4 Standard chemotherapy regimen consists
of concurrent cisplatin (cis) and 5-fluorouracil (5-FU).
Clearly, there is a compelling need to improve the
management of surgical candidates by incorporating
new modalities into the treatment paradigm.
One alternative treatment approach that has been
suggested is immunotherapy. Gene-mediated cytotoxic
immunotherapy (GMCI) constitutes a promising type of
antitumor immunotherapy, and is based on the introduc-
tion of a gene encoding an enzyme capable of transform-
ing a non-toxic prodrug into a cellular toxin that kills
dividing cells in an immunogenic manner. The most well-
developed approach utilizes a replication-defective adeno-
viral vector encoding for the HSVtk protein (AdV-tk).
The HSVtk gene monophosphorylates anti-herpetic
prodrugs, such as ganciclovir (GCV), that are further
phosphorylated by endogenous cellular kinases into active
triphosphate nucleotide analogs. These are incorporated
into cellular DNA and cause cell death.
5 In addition to
its enzymatic effects, AdV-tk/GCV (adenoviral vector
carrying the herpes simplex virus thymidine kinase gene in
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stimulates a strong local and systemic immune response
characterized by a T-helper type 1 cytokine cascade that
manifests with increased interleukin-2, tumor necrosis
factor-a, interferon-g and interleukin-12 production.
6–13
AdV-tk/GCV increases cytotoxic T-lymphocyte infiltra-
tion
5 and increased tumor immunogenicity.
14 It also
stimulates the arrival of natural killer cells
5 and increases
their activity level around neoplastic cells.
15 Overall the
approach has demonstrated a good safety profile and
efficacy in several tumor types, including mesothelioma,
melanoma and others.
16–23 This treatment strategy has
reached clinical trials for several other malignancies such
as prostate cancer,
18,24 ovarian cancer
17 and gliomas.
19
AdV-tk suicide gene therapy has several potential
advantages for the treatment of esophageal cancer. First,
tumors can be accessed directly by endoscopy in humans,
thus allowing for intra-tumoral injection. Secondly,
evidence suggests that this form of immunotherapy
synergizes well with the chemotherapy and radiotherapy,
which is typically employed in patients with esophageal
carcinoma.
16,24–26 Finally, GMCI generates a systemic
immune effect that has the potential to minimize
distant disease that commonly occurs with esophageal
malignancies.
16,26,27
Unfortunately, effective preclinical evaluation of
adjuvant immunotherapy strategies for esophageal carci-
noma has been slow, primarily due to the lack of high-
throughput animal models. Recent reports have described
reliable transgenic murine systems, which develop ortho-
topic lesions, and mimic genetic alterations observed in
human esophageal carcinogenesis. One such immuno-
competent model is the ED-Ls-cyclin-D1;p53
 /  model
described by Opitz et al.
28 However, these models have
many drawbacks, including (1) long periods for tumor
development, (2) inability to monitor disease in real time,
(3) expensive housing and breeding protocols and (4) lack
of access for surgical excision. With these considerations
in mind, syngeneic flank tumor models provide an
optimal mechanism to study adjuvant immunotherapy
strategies in hosts with intact immune systems.
Our aim in this study was to investigate the efficacy of
GMCI in esophageal cancer. Because syngeneic models
have not been reported for esophageal cancer, we first
developed a readily transplantable syngeneic murine
model derived from previously described transgenic mice.
We then tested the clinical effect of AdV-tk in combina-
tion with surgery and standard of care chemotherapy (cis/
5-FU) in our syngeneic murine models of esophageal
cancers. We confirmed the efficacy of the standard
approach using chemotherapy and surgery, but found
the vast majority of animals recurred and ultimately died
of disease, similar to clinical outcomes observed in
humans. We therefore developed a multimodal approach
combining immunotherapy with surgery and chemother-
apy and showed that it was superior to surgery with
adjuvant chemotherapy alone. GMCI further decreased
recurrences and prolonged survival. We found that
preoperative AdV-tk/GCV with chemotherapy and sur-
gery generated a sustained local and systemic CD8 T-cell
response postoperatively. These data suggest that immuno-
therapeutic approaches may be a reasonable modality for
patients with resectable esophageal cancer.
Materials and methods
Animals
Female C57Bl/6 mice (B6, Thy1.2) were purchased from
Charles River Laboratories. Female NOD/SCID/g-chain
knockout (NSG) mice that were bred at the Wistar
Institute (Philadelphia, PA) were used. All mice were
maintained in pathogen-free conditions and used for
experiments at ages 8 week or older. Recognized
principles of laboratory animal care (NIH Publication
No. 85-23, revised 1985) were followed, and the Animal
Use Committees of the Children’s Hospital of Philadel-
phia, the Wistar Institute and the University of Pennsyl-
vania approved all protocols.
Cell lines
AKR is an esophageal cancer cell line established
from the ED-L2-cyclin-D1;p53
–/– mouse as described
previously.
28,29 We also used an independent p53-null
murine esophageal cell line (HNM007) transformed
by HRAS
G12V (ref. 30). In total, 0.5 10
6 of AKR or
HNM007 cells were injected subcutaneously into the
flanks of mice.
For in vitro, studies, we used several human esophageal
cancer cell lines (TE-1 and SEG-1) established from
human squamous cell carcinomas of the esophagus.
31,32
A549 is a human non-small-cell lung cancer (NSCLC)
that we used as a control for in vitro assays.
13 All cell lines
were maintained in D10 media (Dulbecco’s modified
Eagle’s medium supplemented with 10% heat-inactivated
fetal bovine serum, 1% glutamine and 1% penicillin and
streptomycin (P/S)), and cultured at 371C in a humidified
incubator containing 5% CO2.
Chemotherapy
Cis was purchased from APP Pharmaceuticals (Schaum-
burg, IL) and 5-FU was purchased from Sigma-Aldrich
(St Louis, MO). Cis and 5-FU were administered
intraperitoneally (i.p.) once a week to mice at 3 and
85mgkg
 1, respectively. Doses were chosen based on
human equivalent dosing. GCV was purchased from
Roche Laboratories Inc. (Nutley, NJ) and was dosed at
50mgkg
 1, once per day for 5 days, beginning at 2 days
following intratumoral AdV-tk injection. GCV was
suspended in 200ml normal saline for i.p. injections.
Vectors
A non-replicating serotype 5 adenovirus containing the
herpes simplex virus thymidine kinase gene driven by a
Rous sarcoma virus long terminal repeat promoter in the
region of the deleted E1 wild-type adenoviral genes (AdV-
tk) was used. Control adenoviral vector contained the
LacZ gene (Ad.LacZ) in the same position. Both were
produced by Advantagene (Auburndale, MA). AdV-tk
was produced in accordance with good manufacturing
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Cancer Gene Therapypractices (21 CFR210 and 211). The vector has been
characterized for purity and potency and approved for
clinical use. The viral particle (v.p.) per infectious unit
ratio was 10:1. Animals bearing AKR tumors were
treated with intratumoral injections of 1 10
10 v.p. of
AdV-tk or Ad.LacZ. After 48h, GCV therapy was begun.
Determination of in vivo ‘bystander effect’
To study the in vivo bystander effect, NSGs were injected
with AdV-tk-infected AKR cells mixed with varying
numbers of uninfected cells to achieve ratios of infected:
uninfected cells of 1:1, 1:5 and 1:10. In all circumstances,
the number of AKR cells totaled 0.5 10
6. At 6 days after
injection, when all tumors measured approximately
25mm
3 in diameter, the animals were treated with i.p.
GCV (50mgkg
 1 per day) or saline daily for 7 days.
Tumor growth was measured for the next 20 days.
Surgery
Surgery was performed on mice bearing flank tumors
using an established partial resection model.
33 Briefly,
mice bearing flank tumors were anesthetized using
intramuscular ketamine (80mgkg
 1) and xyalazine
(10mgkg
 1), and then shaved with hair clippers. A
1–2cm incision was made immediately adjacent to the
tumor. Resections were completed using standard blunt
dissection. To mimic a positive margin, approximately
10% of the tumor burden was left at the tumor margin.
Careful consideration was given to preserve blood supply
to the remaining tumor volume. Occasionally, it was
necessary to remove skin that was adherent to the tumor.
Skin closure was performed using sterile silk 4-0 sutures.
Buprenorphine (0.2mgkg
 1) was administered at the time
of surgery and 6h after as postoperative analgesia.
Preoperative treatment was unknown to the investigator
performing surgery and making tumor measurements.
The Animal Use Committee of the University of
Pennsylvania and the Wistar Institute approved all
protocols in compliance with the Guide for the Care
and Use of Laboratory Animals.
Determination of adenoviral transduction efficiency
To demonstrate in vitro adenovirus transduction in
esophageal cancer cell lines, AKR, HNM007, TE-1,
SEG-1 and A549 (a human NSCLC with known
transducibility)
13 were transduced with adenoviral vector
carrying a luciferase reporter gene driven by a cytomega-
lovirus promoter (Ad.luciferase). Equal numbers of cells
were transduced with varying concentrations of Ad.luci-
ferase. Ad.luciferase was allowed to infect AKR cells in
Dulbecco’s modified Eagle’s media supplemented with
5% fetal bovine serum, P/S and L-glutamine (D5) for 4h
at 371C. Cells were washed with phosphate-buffered
saline, and then D5 media were added for a 20-h
incubation period. At the end of incubation, cells were
washed twice with phosphate-buffered saline, and then
lysed with 100ml per well of luciferase assay lysis buffer
(Promega Corporation, Madison, WI) for 30min at
room temperature on a standard shaker. The lysed cells
were transferred to a standard white-walled 96-well
luminometer plate (80ml per well). A measure of 100ml
of Luciferase Assay Reagent (Promega) was added
to each well and immediately read in a standard
luminometer at a wavelength of 490nm. Results are
expressed as luminescence (relative light units) vs vector
concentration (v.p. per ml).
In vitro cell viability assays
To evaluate and compare the direct antiproliferative effect
of AdV-tk/GCV on various murine cell lines, cells were
transduced with AdV-tk or control adenovirus (Ad.LacZ)
in T25 flasks at 1 10
6 v.p. per ml. Cultures were
incubated for 24h. After this incubation period, cells were
seeded in quadruplet in 96-well plates (100ml media per
well) at a density of 2 10
3 cells per well and 20mlo f
medium was added containing varying concentrations of
GCV (0–2000mM). Fresh medium containing prodrug was
plated daily for up to day 5. Survival of infected cells
compared with uninfected cells was measured when
uninfected cells reached confluency (usually after 5–8
days after infection) using the MTT (3-(4,5-dimethythia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide) assay, which
is a colorimetric test for the quantitation of cell viability
and proliferation (Cell Titer 96TM Aqueous Nonradio-
active MTT Cell Proliferation Assay; Promega). The
percentage of viable cells were determined using the
following formula:
Viablecellsð%Þ¼ ð A490 ofuntreated   A490 oftreatedÞ
=ðA490 ofuntreatedÞ 100%
In vivo depletion of CD8 T cells
To deplete CD8 T cells during treatment with AdV-tk in
our AKR models, mice received i.p. injections of 200mgo f
monoclonal antibodies purified from the anti-CD8
hybridoma 53-6.7 (obtained from the American Type
Culture Collection, Manassas, VA). Injections were
administered 1 day before beginning AdV-tk/GCV pro-
tocols. Thereafter, a maintenance dose of antibody was
injected i.p. every 3 days throughout the entire experi-
mental period to ensure depletion of CD8 T cells.
Depletion was confirmed by flow cytometry of splenic
suspension.
Immunohistochemical studies
Mice were euthanized at which time tumors were
harvested and frozen in Tissue-Tek OCT compound
(Sakura Finetek USA Inc., Torrance, CA) to be stored
at 801C, and 5mm sections were cut. Monoclonal
antibodies against CD8 T cells (anti-CD8) were obtained
from BD Biosciences and immunohistochemical staining
was performed according to established protocols. Tumor
cell infiltrate was quantified by counting the number of
positively stained cells in four high-powered ( 400)
fields. Five slides for each specimen were analyzed.
Flow cytometric analysis of tumors
For flow cytometric analysis, tumors were removed from
euthanized mice and minced into fine pieces in digestion
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 1 DNase I and 2.0mgml
 1
collagenase type IV (Sigma, St Louis, MO). Samples were
incubated in digestion buffer at 371C for 30min, filtered
through a 70-mm filter and washed twice with R10. Fc
receptors were blocked with anti-mouse CD16/CD32
antibodies (BD Biosciences Pharmingen, San Diego,
CA). Following one wash with phosphate-buffered saline
plus 2% fetal bovine serum (staining buffer), cells were
incubated for 30min at 41C with appropriate antibodies
obtained from BD Biosciences PharMingen and used at
the indicated dilutions for flow cytometry: CD45-PerCP
(1:200) and CD8-APC (1:200). Samples were then washed
and resuspended in staining buffer or fixed in 2%
paraformaldehyde. Flow cytometry was completed using
a Becton Dickinson FACS Calibur flow cytometer (San
Jose, CA), and analyzed using the FlowJo software
(Ashland, OR).
Winn assay for the detection of tumor-neutralizing cells
Splenocytes were isolated from spleens (2 mice per group)
that were harvested 3 days after the first dose chemother-
apy was administered to mice receiving AdV-tk/surgery/
chemo and Ad.LacZ/surgery/chemo protocols. CD8 T
cells were separated from the total splenocyte pool using
MACS isolation system (CD8a [Ly-2] mouse MicroBeads;
Miltenyi Biotec, Auburn, CA). The isolated cells consisted
of greater than 90% CD8 T cells, as confirmed by
fluorescence-activated cell sorter analysis. Fresh AKR
cells were mixed with CD8 T cells (Winn assay) in a ratio
of 3 CD8 T cells:1 AKR tumor cell. The resulting mixture
(1.5 10
6 CD8 T cells:0.5 10
6 AKR tumor cells) was
injected subcutaneously into the flanks of five naı¨ve
C57Bl/6 mice. A control group of five mice with AKR
cells alone (0.5 10
6 cells) were injected in an analogous
manner. Tumor size was assessed over the next 7 days.
Statistical analyses
For flow cytometry, immunohistochemistry and flank
tumor volume studies comparing differences between two
groups, we used unpaired Student’s t-tests. For studies
comparing more than two groups, analysis of variance
with appropriate post hoc testing was implemented.
Kaplan–Meier curves were utilized to determine post-
operative median survival. Postoperative survivals
(defined as the time from surgery to the time that flank
tumor volume reached 1500mm
3) for treatment groups
were compared using the log-rank statistic. Differences
were considered significant when Po0.05. Data are
presented as mean (s.e.), unless otherwise noted.
Results
Treatment of esophageal cancer model with Cis/5-FU
and surgery has limited efficacy
To examine the efficacy of the current standard of care
chemotherapy regimen for esophageal cancer in our
models, we evaluated human equivalent dosing of cis/5-
FU in the murine esophageal carcinoma model, AKR.
Moderate-sized flank tumors (250mm
3) were treated with
human equivalent dosing of Cis (3mgkg
 1) and 5-FU
(85mgkg
 1). Animals were given two doses of chemo-
therapy, 1 week apart, i.p. We observed a reduction
in the tumor volume or delay of tumor growth from
chemotherapy administration (Figure 1a). By day 19,
the mean tumor volume was 775mm
3 in mice randomized
to control treatment vs 398mm
3 in mice randomized to
cis/5-FU (P¼0.03) (Figure 1b). All mice ultimately
required being killed owing to excessive tumor burden.
These results were confirmed with repeat experiments.
Increasing concentrations of cis/5-FU were toxic to
animals, and did not significantly alter tumor growth
kinetics (data not shown). Results in our AKR model
were similar to those observed in humans, confirming that
the model accurately reflects the limited efficacy of cis/5-
FU in esophageal cancer.
Next, the efficacy of cis/5-FU in decreasing post-
operative local recurrences in the AKR model was
evaluated. Again, C57Bl/6 mice were injected with AKR
cells in the subcutaneous flank. Large flank tumors
(B500mm
3) were incompletely resected to mirror the
scenario of a positive margin that may occur following
surgery. On postoperative day 3, animals were rando-
mized to treatment with cis/5-FU or normal saline
injections. Animals were given two doses of chemother-
apy or saline, 1 week apart. In both groups, all mice
undergoing surgery were observed to have locally
recurrent disease, although we observed a temporary
reduction in tumor volume after chemotherapy adminis-
tration (Figure 1c). At postoperative day 10, the mean
tumor volume of the control mice was 835 vs 402mm
3 in
mice randomized to surgery vs chemotherapy following
surgery, respectively (P¼0.03) (Figure 1d). Similar to
non-surgical models, tumors promptly returned to normal
growth and ultimately overcame all mice following
chemotherapy cessation. These experiments demonstrated
that chemotherapy has marginal benefits in preventing
disease progression in a positive margin setting, and that
the model reflects human clinical experiences.
Taken together, these experiments demonstrate that the
AKR esophageal cancer model resembles human esopha-
geal malignancies in terms of its modest susceptibility to
cis/5-FU chemotherapy regimen. In addition, these results
suggest that the AKR model may be a candidate
esophageal carcinoma model to test preclinical models
involving standard chemotherapy treatment and surgical
intervention.
Human and murine esophageal carcinoma cells are
sensitive to AdV-tk/GCV
There have been conflicting reports on the efficiency of
serotype 5 adenovirus-transducing esophageal carcino-
mas.
34,35 Thus, we sought to test serotype 5 adenovirus
transduction in murine and human esophageal cancer cell
lines in an in vitro setting. Using Ad.luciferase, a serotype
5 adenovirus similar to AdV-tk, we transduced two mouse
cell lines (AKR and HNM007) and two human esopha-
geal cancer lines (SEG-1 and TE-1) at vector concentra-
tions ranging from 0 to 2.5 10
9 v.p. per ml. A known
susceptible human NSCLC (A549)
13 was used as a
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Cancer Gene Therapypositive control. Although AdV-tk/GCV therapy does not
require 100% transduction efficiency to stimulate an
immune response, some transduction is required to release
tumor antigens and initiate an immunological response.
Both human lines (TE-1, SEG-1) and one mouse line
(HNM007) showed transduction efficiencies comparable
to A549, whereas the AKR cells were up to 100-fold less
susceptible at each vector concentration (Figure 2a).
These results showed that serotype 5 adenovirus
constructs, including AdV-tk, have the potential to
transduce adequately both human and murine esophageal
carcinoma cells.
To further evaluate the efficacy of AdV-tk/GCV
therapy in vitro, we first tested the most stringent
model—the murine esophageal cancer model, AKR.
AKR cells were transduced with AdV-tk or Ad.LacZ
(control) at 1 10
6 v.p. per ml and the cells were exposed
to varying doses of GCV (range 0–2000mM; note that
human peak GCV serum concentrations are between 20
and 200mM). The direct cytotoxic effect was evaluated by
MTT assay (Figure 2b). GCV exerted cytotoxic effects on
AdV-tk-transduced AKR cells in a dose-related manner.
We observed that the half-maximal inhibitory concentra-
tion in this MTT assay was found to be at a GCV
concentration of 200mM, which is consistent with a low
efficiency. These doses are similar to concentrations, we
have used in NSCLC cell lines (unpublished data). We
next carried out a similar assay for the HNM007 cell line
(Figure 2c). We again observed a dose-dependent
response; however, the half-maximal concentration was
found to be at a GCV concentration of 20mM, which was
consistent with a slightly higher level of efficiency when
compared to AKR.
These data provide evidence that AdV-tk/GCV is
directly cytotoxic and potentially useful in the treatment
of human esophageal carcinomas. In addition, the AKR
model appears to be less susceptible to GCV and AdV-tk
transduction; thus, it will likely provide a more stringent
in vivo model.
AdV-tk/GCV is effective in in vivo syngeneic murine
models of esophageal cancer
We next examined the efficacy of AdV-tk/GCV therapy in
mice bearing flank AKR tumors. AKR tumor cells were
injected subcutaneously into C57Bl/6 mice. When the
established flank nodules reached a size of 250mm
3,a n
intratumoral injection of 1 10
10 v.p. of AdV-tk or
Ad.LacZ (control) was administered. After 2 days, we
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Figure 1 Cisplatin (Cis) and 5-fluorouracil (5-FU) in the murine esophageal carcinoma model, AKR. (a) Cis and 5-FU in AKR (no surgery). Cis/
5FU was administered at days 13 and 19 in mice (n¼9) bearing AKR flank tumors. Control mice (n¼8) were administered normal saline at days
13 and 19 as a control. After chemotherapy protocol completion, tumors resumed normal growth rates and mice required being killed owing to
tumor burden. (b) Bar graph demonstrating tumor volumes at day 19. (c) Postoperative Cis and 5-FU in AKR. Mice were administered cis/5-FU
following surgery (n¼10) on postoperative days 3 and 10. Control mice (n¼10) received normal saline injections. As observed in mice not
undergoing surgery, chemotherapy administration decreased tumor volume, but did not result in complete tumor eradication. All mice had
recurrences, and ultimately were killed owing to excessive tumor burden. (d) Demonstration of flank tumor volumes at postoperative day 10.
*Po0.05; **Po0.01; arrowheads signify time of chemotherapy administration.
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Cancer Gene Therapyadministered GCV at a dose of 50mg i.p. daily, for 5 days.
AdV-tk/GCV significantly inhibited tumor growth in this
model; at day 26, the mean tumor volume of control mice
was 1016 vs 338mm
3 in mice receiving AdV-tk/GCV;
P¼0.004 (Figures 3a and b). All mice randomized to
AdV-tk/GCV appeared healthy, suffered no weight loss
and tolerated the treatment well. However, no mice were
cured, and tumors ultimately grew and animals required
being killed owing to tumor burden.
To determine if a bystander effect occurred in AKR
tumors growing in vivo, cells were infected with AdV-tk
in vitro and mixed with various concentrations of non-
transduced AKR cells 24h after infection (under these
conditions, no contamination of cells via residual
adenovirus could occur). The cell mixtures were injected
into the flanks of NSG mice (lack B cells, T cells,
macrophages and NK cells) and allowed to grow to
measurable size (day 6), at which time animals were then
treated with i.p. GCV for 7 days. As shown in Figure 3c,
all tumors containing AdV-tk-transduced cells demon-
strated strong regression as compared to tumors consist-
ing of uninfected AKR cells. The strongest effects were
observed in tumors grown from 100% infected AKR cells;
however, even those derived from mixtures of infected:
uninfected cells at ratios 1:1, 1:5 and 1:10 displayed strong
regression (Po0.01) (Figure 3d). These experiments show
that a strong cytotoxic bystander effect is operative in
adenovirus-transduced AKR tumors in vivo.
Previous reports have described that acquired immune
responses are a primary mechanism of the effects of
GMCI systems.
12–14 To more precisely define this role in
our AKR model and AdV-tk system, mice bearing
established AKR flank tumors were randomized to four
groups: (1) Ad.LacZ/GCV treatment (control); (2)
Ad.LacZ/GCV with CD8 T-cell depletion; (3) AdV-tk/
GCV; or (4) AdV-tk/GCV with CD8 T-cell depletion.
Depletion of the T-cell population was confirmed weekly
by analysis of spleen cells by flow cytometry (data not
shown). Although mice receiving AdV-tk/GCV had
smaller nodules after 26 days of tumor growth, effects
were negated in the presence of CD8 T-cell depletion
(Figures 3e and f). In fact, mice randomized to CD8 T-cell
depletion protocols were observed to have more rapid
growth, regardless of administration of AdV-tk/GCV and
experienced more rapid growth (Figure 3e). These results
confirm the role of CD8 T cells as an essential element in
antitumor effects of AdV-tk/GCV protocols in our
esophageal carcinoma models.
These experiments demonstrate in vivo evidence that
AdV-tk/GCV therapy provides benefit with regard to
tumor reduction in murine models of esophageal carci-
noma. Our data in the NSG mice, as well as previous data
using GMCI approaches, demonstrates that a bystander
effect is observed when a sufficient number of tumor cells
is infected. Given the rapid growth of the AKR line and
the intratumoral delivery method, it is most likely that
only a small percentage of tumor cells were infected; thus,
only a small bystander effect was in wild-type mouse
experiments. Although small, it appears that this mechan-
ism of death generates a strong immunological response
Figure 2 In vitro transduction and efficacy of type 5 adenovirus (Ad.luciferase) and AdV-tk/GCV (adenoviral vector carrying the herpes simplex
virus thymidine kinase gene in combination with the prodrug ganciclovir) therapy for esophageal cancer models. (a) In vitro transduction
of Ad.luciferase for esophageal cancer models. To determine in vitro transduction efficiency of human esophageal carcinomas (H-Eso) SEG-1,
TE-1; murine esophageal carcinomas (M-Eso) AKR, HNM007; and A549 (human NSCLC line used as positive control) were transduced with
Ad.luciferase at varying concentrations. Transduction efficiency was proportional to relative light units. SEG-1, TE-1 and HNM007 demonstrated
high levels of transduction consistent with A549, whereas AKR was 10- to 100-fold more resistant to transduction. Next, in vitro efficacy of AdV-
tk/GCV was investigated in the murine models of esophageal carcinoma (b) AKR and (c) HNM007. Cells were transduced at 1 10
6 viral
particles per ml with AdV-tk or Ad.LacZ (control), and then treated with varying concentrations of the prodrug, GCV. The half-maximal inhibitory
concentration for AKR cells was 200mM and for HNM007 cells was 20mM.
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Cancer Gene Therapydependent on CD8þ T-cell trafficking. Taken together,
these findings suggest an intricate interplay between
cytotoxic effects (bystander effects) and a robust anti-
tumor response driven by CD8 T cells.
Neoadjuvant AdV-tk/GCV decreases postoperative
cancer recurrences
We next evaluated the efficacy of the AdV-tk/GCV
regimen in limiting postoperative local recurrences using
the positive margin model. C57Bl/6 mice were again
injected with AKR cells into the subcutaneous flank. At
day 9 following tumor cell inoculation, when the tumors
reached a volume of B250mm
3, mice were administered
intratumoral AdV-tk or Ad.LacZ at a concentration of
1 10
10 v.p. After 2 days, GCV was administered for 5
days, followed by ‘positive margin’ surgery on day 17. All
mice undergoing surgery were observed to have a local
recurrence; however, recurrent tumor volumes in the
group receiving AdV-tk/GCV were significantly reduced
postoperatively (Figures 4a and b). By postoperative day
14, the mean recurrent tumor volume in control mice
was 1434 vs 735mm
3 in mice receiving neoadjuvant
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Cancer Gene TherapyAdV-tk/GCV therapy; P¼0.03. Again, all mice rando-
mized to AdV-tk/GCV appeared healthy. No mice were
cured from this treatment, and all ultimately succumbed
to disease burden. Although not curative as a mono-
therapy, these results suggest a potential adjuvant role for
GMCI in limiting recurrent tumor growth in models of
esophageal carcinoma.
Neoadjuvant AdV-tk/GCV followed by surgery and
chemotherapy significantly decreases recurrent disease
progression
Evidence in other tumor models indicates a synergy
between AdV-tk/GCV and chemotherapy.
36–38 We
hypothesized that AdV-tk/GCV followed by surgery and
cis/5-FU would similarly provide superior effects in
limiting postoperative recurrences with minimal addi-
tional toxicity. To test this, AKR cells were injected into
the flanks of C57Bl/6 mice. Once flank tumors reached a
volume of 250mm
3,1 10
10 v.p. of AdV-tk or Ad.LacZ
was given intratumorally. After 2 days, we administered
i.p. GCV therapy daily for 7 days. Following completion
of AdV-tk/GCV or Ad.LacZ/GCV therapy, surgery was
performed, leaving approximately 10% of tumor volume.
At postoperative days 3 and 10, cis/5-FU was adminis-
tered in an i.p. manner as described previously.
As in the single-agent studies described above, we
observed a modest reduction in tumor progression in
animals receiving AdV-tk/GCV or chemotherapy as
monotherapy. However, in mice randomized to combina-
tion therapy, we observed substantial additional reduc-
tion in tumor growth when compared to control mice and
mice receiving monotherapies (Figure 5a). At postopera-
tive day 14, recurrent tumor volumes of control mice,
mice receiving AdV-tk/GCV, cis/5-FU or combination
were 1434, 886, 744 and 345mm
3, respectively (P¼0.007)
(Figure 5b). Although no mice were cured in any
treatment groups, we observed almost a twofold increase
in postoperative median survival in mice receiving
combination therapy vs those receiving monotherapy
(Figure 5c). By Kaplan–Meier analysis with log-rank
testing, median postoperative survival for control, AdV-
tk/GCV, cis/5-FU and combination groups was 18, 21.5,
24 and 34 days, respectively (Po0.001). Of note, all mice
receiving combination therapy appeared healthy without
signs of systemic toxicity throughout the duration of the
experiment.
These results suggest that addition of AdV-tk/GCV
with standard chemotherapy protocols and surgery result
in superior outcomes following surgery. This regimen
appears to be well tolerated and highly effective in
postoperative survival, although no mice were cured.
Even though no cures were observed, the significant
increases in postoperative survival are encouraging
and offer a potentially life-prolonging intervention for
patients diagnosed with operable esophageal carcinoma.
Preoperative in situ GMCI increases intratumoral
trafficking of CD8 T cells postoperatively
To further assess the mechanistic role of AdV-tk/GCV
treatment, we performed immunohistochemical staining
on selected tumor sections. Mice bearing flank AKR
tumor were again treated with Ad.LacZ or AdV-tk/GCV,
followed by surgery and postoperative cis/5-FU. Tumors
were harvested at 3–5 days after the first dose of
postoperative chemotherapy. In both groups, staining
with hematoxylin and eosin revealed the presence of a
large area of central necrosis with a diffuse infiltration of
white cells into the tumor, whereas a peripheral rim of
intact tumor tissue was noted (data not shown).
Immunohistochemical CD8 staining demonstrated
an increased intratumoral CD8 T-cell trafficking in
mice receiving AdV-tk/GCV therapy vs those receiving
Ad.LacZ/GCV; 13.6 vs 4.2 cells per high power field
(P¼0.009) (Figure 6a).
To further assess the intratumoral CD8 T-cell traffick-
ing associated with AdV-tk/GCV therapy, we digested the
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Cancer Gene Therapyresidual tumors and performed fluorescence-activated cell
sorter analysis. At the same time, tumors were harvested
for staining, and were also processed for flow cytometric
analysis. We noted that mice receiving AdV-tk/GCV had
a significant increase in the percentage of CD8 immuno-
cytes (8.15% vs 14.89%; P¼0.02) of CD8 cells
(Figure 6b). To confirm that CD8 T cells were responsible
for this antitumor effect, we isolated CD8 T cells from
mice 3 to 5 days following the first dose of postoperative
chemotherapy. These CD8 T cells were injected along
with fresh AKR tumor cells (in a ratio of 3 CD8 T cells:1
AKR cell) into the flank of tumor-naı¨ve C57bl/6 mice.
AKR cells were injected alone in five mice to tumor cell
viability. The growth of these nodules was then observed
for 7 days. We found that CD8 T cells obtained from mice
receiving both neoadjuvant AdV-tk/GCV and postopera-
tive chemotherapy were better able to neutralize AKR
cells as compared to mice receiving either monotherapy
alone (P¼0.02) (Figure 6c). These results suggest that
neoadjuvant in situ GMCI decreases tumor burden
primarily by augmentation of antitumor CD8 T-cell
function.
Discussion
To our knowledge, this report marks the first study
utilizing immunotherapy in a syngeneic murine model of
esophageal cancer. In this report, we demonstrate that
neoadjuvant GMCI in conjunction with surgery and cis/5-
FU has a strong effect in impeding recurrent tumor
growth and improving postoperative survival in our novel
murine models of esophageal cancer. The mechanism
underlying these benefits arises from (1) direct cytotoxic
effects and (2) augmentation of adaptive host immune
system locally at the site of surgical resection. Similar
studies examining the role of adjuvant immunotherapies
for esophageal cancer have been lacking owing to the
paucity of high-throughput esophageal cancer models,
which can be readily utilized for preclinical evaluation.
Immunotherapy approaches augment the host’s adap-
tive immune system to eliminate residual cancer cells,
which may persist after debulking with standard thera-
pies. This approach is attractive as a surgical adjuvant for
a number of reasons. First, immunotherapy is most
successful for small tumor burdens. Therefore, esophageal
resection and chemoradiation eliminate large tumor
burden, whereas immunotherapy offers the potential to
eliminate residual disease.
39,40 Second, immunotherapy
has minimal toxicity, lack of dependence on rapidly
dividing cells, and the ability to generate long-standing
antitumor memory. Third, immunotherapy has recently
been demonstrated to synergize with chemotherapy and
radiotherapy to augment the antitumor effect of each
individual modality.
24,38
The development of immunocompetent syngeneic
murine models is critical for the study of adjuvant
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Cancer Gene Therapyimmunotherapy, as there is an array of evidence suggest-
ing that a complex set of immune responses that occur
during the perioperative period: (i) the generation of an
endogenous antitumor immune response (concomitant
immunity);
41 (ii) the well-known phenomenon of peri-
operative immunosuppression;
42 and (iii) the immunolo-
gical consequences associated with wounds and wound
healing.
43 Our recent development of two syngeneic
esophageal carcinoma lines, AKR and HNM007, has
allowed us to examine immunotherapies, and ultimately
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Cancer Gene Therapydetermine their effects with the presence of these surgical
variables. Our AKR model incorporates both genetic
(cyclin-D1 overexpression and p53 deletion) and physiolo-
gical (resistance to standard platinum-based chemotherapy
regimen) similarities to human esophageal carcinomas.
Until recently, the combination of immunotherapy with
chemotherapy has not been investigated because of
theoretical fears that the antiproliferative effects of
chemotherapy (seen clinically as post-chemotherapy
leukopenia) would eliminate antitumor directed lympho-
cytes. An increasing number of preclinical and clinical
studies, including work by our own group,
38 have recently
shown that immunotherapy is not only compatible, but
may act synergistically with certain chemotherapies. Our
observations suggest that such a cooperation exists
between AdV-tk/GCV and standard cis/5-FU used in
esophageal cancer management. With consideration of
our findings, it is conceivable that other immunotherapy
approaches may also offer alternative approaches to
manage patients with esophageal cancer, without adding
unnecessary toxicities.
The mechanisms responsible for this unique combina-
tion between immunotherapy and subsequent chemother-
apy have not been fully explored. Our group has provided
evidence suggesting that this markedly augmented effect
could partially be explained by a ‘prime and boost’
phenomenon.
38 To further describe, viral immunogene
therapy initially induces effector antitumor T cells (the
prime). After the initial elimination of tumor cells,
chemotherapy agents serve to augment (the boost) the
immune response by providing additional antigen and
tumor danger signals to antigen-presenting cells that
re-activate memory antitumor T cells, and altering
the tumor microenvironment.
38 We provide additional
evidence that immunotherapy (GMCI) synergizes with
chemotherapy (cis/5-FU) and surgery and reduces recur-
rent tumor growth and enhances survival in our murine
models of esophageal carcinoma. In addition, following
treatment of esophageal flank tumors with preoperative
AdV-tk/GCV, we noted increased trafficking of CD8
T cells into recurrent tumors by immunohistochemistry.
These data support the notion that AdV-tk/GCV func-
tions by an immune pathway. In addition to local effects,
previous studies suggest that systemic CD8 T cells also
increase, which reflects the ability of preoperative therapy
to generate prolonged antitumor responses.
In summary, this report describes the first successful
study demonstrating cooperative effects of immunother-
apy with standard chemotherapy and surgery for esopha-
geal carcinoma using our newly developed syngeneic
murine models. We have found that this treatment
protocol provides both significant decreases in disease
progression and postoperative survival, with minimal
morbidity and mortality. The primary effects of this
regimen are elicited via increases in CD8 T-cell trafficking
within the tumor. We also present initial in vitro evidence
supporting the notion that a human response will mirror
(and potentially supersede) our murine preclinical find-
ings, as the human esophageal cancer cells were more
susceptible to AdV-tk-mediated killing than murine
tumor cells. Although additional studies are likely
required to most efficiently translate these results to the
clinical arena, the results nonetheless demonstrate that
protocols incorporating inmmunotherapies have the
potential to dramatically improve outcomes for those
diagnosed with esophageal cancer.
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